FRE.DE - Fresenius SE & Co. KGaA

Edited Transcript of FRE.DE earnings conference call or presentation 30-Jul-19 11:30am GMT

Q2 2019 Fresenius SE & Co KGaA Earnings Call

UPDATE 1-Fresenius raises 2019 sales outlook after Q2 hits targets

Fresenius raises full-year outlook after Q2 meets expectations

Why Fresenius Is the Initial Winner From Trump's Kidney Disease Overhaul

Fresenius appears better prepared than DaVita for market transition from outpatient to home dialysis caused by the Trump kidney initiative Continue reading...

INSIGHT-Will Europe's clampdown on faulty medical devices hurt patients?

When a Californian company founded by a U.S. veteran wounded in Afghanistan sought to register a new medical device this year, it turned to Europe before the United States. "Now it has flipped," said Bill Colone, CEO of San Clemente-based Spinal Singularity, which hopes to launch a 'smart' catheter for men with spinal injuries or disease early next year after squeezing in its application under the old European rules. Colone is part of a chorus of industry voices warning that a switch to stricter European rules governing medical devices, due to come into force a year from now, will slow or even halt the release of products in Europe that could transform patients' lives.

Fresenius Finance Ireland II Plc -- Moody's announces completion of a periodic review of ratings of Fresenius SE & Co. KGaA

Moody's Investors Service ("Moody's") has completed a periodic review of the ratings of Fresenius SE & Co. KGaA and other ratings that are associated with the same analytical unit. The review was conducted through a portfolio review in which Moody's reassessed the appropriateness of the ratings in the context of the relevant principal methodology(ies), recent developments, and a comparison of the financial and operating profile to similarly rated peers. This publication does not announce a credit rating action and is not an indication of whether or not a credit rating action is likely in the near future.

Fresenius talking to potential suitors about sale of blood transfusion business - sources

Fresenius has approached potential suitors about the sale of its blood transfusion business, two people with knowledge of the matter said on Friday. Fresenius has hired Goldman Sachs to explore the sale, the people said.

Edited Transcript of FRE.DE earnings conference call or presentation 2-May-19 11:30am GMT

Q1 2019 Fresenius SE & Co KGaA Earnings Call

CTSO: Distributor Sales Take a Breather But Expected to Rebound. Direct Sales Remain Robust

Q1 2019 Update: Distributor Sales Take a Breather But Expected to Rebound. CytoSorbents (CTSO) reported financial results for their first quarter ending March 31st and provided a business update. While grant revenue was inline with expectations, product sales were a relative dud.

Fresenius makes solid start to year after turbulent 2018

Fresenius reported a rise in first-quarter sales and operating profit on Thursday, helped by growth at its generic infusion drugs and dialysis units, as its troubled German hospital business showed signs of stabilisation. Currency-adjusted quarterly sales rose 5 percent to 8.5 billion euros (£7.3 billion), helped by growth at its Kabi infusion unit and separately listed Fresenius Medical Care. "All four Fresenius business segments have developed in line with our expectations, putting us well on course to meet our targets for the year," Chief Executive Stephan Sturm said.

Fresenius: 1Q Earnings Snapshot

On a per-share basis, the Bad Homburg, Germany-based company said it had net income of 50 cents. Earnings, adjusted for non-recurring costs, came to 59 cents per share. The dialysis services provider posted ...

FDA flags concerns at Akorn's Amityville plant, shares slip

Generic drugmaker Akorn Inc said on Thursday the U.S. Food and Drug Administration had raised concerns about its manufacturing plant in Amityville, New York, that included a lack of records on the maintenance and cleaning of equipment. The FDA's issuance of the notice following an inspection of the plant, through a so-called Form 483, is the latest in a series of setbacks for Akorn and comes a month after the agency issued a warning letter related to another plant. The agency, following an inspection of the plant, also observed deficiencies in the facility's systems for keeping its equipment free from contamination, the FDA said in the form https://www.sec.gov/Archives/edgar/data/3116/000117184319001306/exh_992.htm dated Feb. 13.